IQ-AI, Ltd.

IQ-AI, Ltd.

  • News & Announcements
  • Shareholder Information
  • Investor Relations
  • Significant Shareholders
  • Publications
  • Home
  • Corporate News & Announcements
  • IQ-AI News & Announcements
  • Orphan Drug Designation Status
 

BLOG

IQ-AI
Tuesday, 28 February 2023 / Published in IQ-AI News & Announcements

Orphan Drug Designation Status

/**/
RNS Number : 3886R
IQ-AI Limited
28 February 2023
 

IQ-AI Announces Orphan Drug Designation Status

FDA grants orphan status to Gallium Maltolate for treating GBM

IQ-AI Limited, (LSE: IQAI) (OTCQB: IQAIF), is pleased to announce that the United States Food and Drug Administration (FDA) has granted orphan drug designation (ODD) status for gallium maltolate (GaM) for the treatment of glioblastoma multiforme (GBM) brain cancer. GaM is the oral agent under study in IQAI’s sponsored Phase I clinical trial being conducted at the Medical College of Wisconsin (MCW) in Milwaukee, Wisconsin.

 

ODD status is given to drugs that show promise in treating rare diseases or conditions that affect fewer than 200,000 people in the United States. These diseases are typically serious or life threatening. In 1983, the US government passed the Orphan Drug Act to provide companies with certain benefits for developing orphan drugs with the goal of accelerating drug development for these patients.

 

The ODD status is independent of the overall approval process by the FDA. However, as the clinical trial continues, IQAI intends to take full advantage of the benefits orphan designation offers including assistance in the drug development process, tax credits, grant opportunities, and seven years of market exclusivity post-approval.

 

Enrolment is ongoing in the Phase I clinical trial to evaluate the safety and tolerability of GaM and to identify the recommended phase 2 dose (RP2D) necessary for a Phase II clinical trial. A Phase II clinical trial, the next major developmental step, will be undertaken to officially assess if GaM works in GBM.

 

“This designation is a critical milestone in the development of GaM. It brings the possibility of making an oral agent available as a treatment option for glioblastoma multiforme brain cancer, closer to reality,” said Trevor Brown, CEO of IQ-AI Limited.

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

 

For further information, please contact:

 

IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

About IQ-AI Limited

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Article source
  • Tweet

What you can read next

IQ-AI’s David Smith updates on patents and StoneChecker FDA process
Holding in Company
Orphan Drug Designation for GaM in Pediatric GBM

Recent Posts

  • IQ-AI shares cease trading on the OTCQB

    /**/ RNS Number : 9599M IQ-AI Limited 19 Septem...
  • Reduced Gadolinium Approach Validated’

    /**/ RNS Number : 7871L IQ-AI Limited 08 Septem...
  • Update on Collaboration Agreement with Mayo Clinic

    /**/ RNS Number : 8096J IQ-AI Limited 18 August...
  • IB & GE HealthCare Enter into Commercial Agreement

    /**/ RNS Number : 8077J IQ-AI Limited 18 August...
  • Half-year Report

    /**/ RNS Number : 5460J IQ-AI Limited 17 August...
  • Policies
  • Investor Information

iq-ai@imagingbiometrics.com

P. O. Box 264
Forum 4, Grenville Street
St Helier, Jersey, Channel Islands
JE4 8TQ

Copyright © 2015-2023 IQ-AI. All Rights Reserved
TOP
Our website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT